Fusion Antibodies (FAB) Competitors

Fusion Antibodies has higher revenue and earnings than Poolbeg Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

In the previous week, Poolbeg Pharma had 5 more articles in the media than Fusion Antibodies. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Fusion Antibodies. Fusion Antibodies' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.08 indicating that Fusion Antibodies is being referred to more favorably in the news media.

5.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Poolbeg Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. Poolbeg Pharma's return on equity of -71.28% beat Fusion Antibodies' return on equity.

Poolbeg Pharma has a beta of 1.828, meaning that its share price is 83% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, meaning that its share price is 24% more volatile than the broader market.

Fusion Antibodies has a beta of 1.244, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 59.4% of e-therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.

Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

hVIVO has higher revenue and earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

hVIVO has a beta of 1.694, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, suggesting that its share price is 24% more volatile than the broader market.

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 151.89%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Fusion Antibodies.

hVIVO has a net margin of -31.76% compared to Fusion Antibodies' net margin of -54.45%. hVIVO's return on equity of -35.13% beat Fusion Antibodies' return on equity.

In the previous week, hVIVO had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Fusion Antibodies. hVIVO's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, meaning that its stock price is 24% more volatile than the broader market.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. Fusion Antibodies' return on equity of -97.87% beat Hemogenyx Pharmaceuticals' return on equity.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Hemogenyx Pharmaceuticals had 6 more articles in the media than Fusion Antibodies. MarketBeat recorded 6 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Fusion Antibodies. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Fusion Antibodies' score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the media.